Researcher at Fox Chase Cancer Center wins a new Cytation™ 3 Cell Imaging Multi-Mode Reader in BioTek's "Think Possible" Application Contest

Published on April 14, 2014 at 10:41 AM · No Comments

BioTek congratulates Dr. Jeff Peterson of the Fox Chase Cancer Center in Pennsylvania for winning a new Cytation™ 3 Cell Imaging Multi-Mode Reader in BioTek's "Think Possible" Application Contest. Entrants were judged on a short essay that they submitted, detailing the application that they think is possible for their specific research using the Cytation 3. As an Associate Professor, Dr. Peterson studies chemical biology and kinase signaling in cancer.

"Multiplexing of disparate assays using multiple detection modalities is the future," Dr. Peterson wrote as part of his essay. "Cytation 3 is the first instrument that I am aware of that bridges the gap between imaging-based phenotypic screening and targeted assays using biochemical readouts. When both approaches are feasible simultaneously, the debate between phenotypic and targeted screening approaches dissolves to reveal a new world of possibilities."

As Dr. Peterson noted in his essay, patent pending Cytation 3 provides both quantitative and phenotypic cellular analyses by combining automated digital fluorescence microscopy and conventional microplate detection in a single platform. Multi-channel widefield fluorescence and brightfield imaging are supported using high-intensity LED light sources and onboard filter cubes, and automated functions allow increased throughput compared to manual microscopy systems. Hybrid Technology™ multi-mode detection combines high sensitivity filter-based detection and flexible monochromator-based detection for unmatched assay versatility now and in the future. This modular, parallel data acquisition platform allows scientists to collect more meaningful data, increase sample throughput, and reduce experimental time.

Cytation 3 is the recipient of three awards since its launch: the MipTec New Product Innovation Award, the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award, and Thermo Fisher Scientific "Extraordinary New Product Line Award". It is also a finalist in the 2014 Edison Awards® competition. For additional information on Cytation 3's capabilities, visit www.cytation3.com.

Congratulations to Dr. Peterson and Fox Chase Cancer Center!

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. These technologies are used to aid life science research, facilitate drug discovery, provide rapid and cost-effective analysis, and enable sensitive, accurate quantification of molecules across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations. As such, they are often honored for local accomplishments and technological innovations, including Best Places to Work in Vermont, North American New Product Innovation Award for Workflow Solutions in Life Sciences and Drug Discovery Product of the Year – Scientists' Choice Award.

Posted in: Device / Technology News

Tags: , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Statistical analysis shows stage of breast cancer predicts treatment choice